3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Colorectal Neoplasms
14
Rectal Neoplasms
5
Neoplasm Metastasis
5
Cholangiocarcinoma
4
Stomach Neoplasms
3
Colonic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Hepatocellular
3
Biliary Tract Neoplasms
3
Adenocarcinoma Of Esophagus
3
Ovarian Neoplasms
2
Neoplasms
2
Gastrointestinal Neoplasms
2
Gallbladder Neoplasms
2
Esophageal Neoplasms
2
Recurrence
1
Pathologic Complete Response
1
Lung Neoplasms
1
Gastroesophageal Adenocarcinoma
1
Endometrial Neoplasms
1
Disease Progression
1
Central Nervous System Neoplasms
1
Carcinoma, Basal Cell
1
Breast Neoplasms
1
Bile Duct Neoplasms
1
Adenocarcinoma of the Lower Rectum
1
Adenocarcinoma
1
Interventions
Gemcitabine
9
Cisplatin
9
pembrolizumab
5
durvalumab
3
Specimen Handling
3
Platinum
3
Oxaliplatin
3
Leucovorin
3
1,2-diaminocyclohexaneplatinum II citrate
3
Taxes
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Folfox protocol
2
Fluorouracil
2
Biopsy
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
zanidatamab
1
trastuzumab deruxtecan
1
peposertib
1
dehydroftorafur
1
binimetinib
1
avelumab
1
Trastuzumab
1
Tegafur
1
S 1 (combination)
1
Radiation Dose Hypofractionation
1
Radiation
1
Paclitaxel
1
Lymph Node Excision
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Gallbladder Neoplasms
×
Folfox protocol
×
90 days
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts
NCT07265674
2026-05-14
Beacon-BTC
J-Pharma Co., Ltd.
Phase 3
Recruiting
480 enrolled